The Swiss drug company Novartis is set to sidestep mounting controversy over its xenotransplantion research in Britain by shutting its UK subsidiary Imutran. It is collaborating with the US-based company BioTransplant to set up a company that will conduct the research in Massachusetts.
Imutran researchers have transplanted pig organs into monkeys, with a view to developing the technique for use in humans. But some scientists are concerned about the potential for retroviruses — inactive and harmless in the pig genome — to become infectious in humans. In addition, animal rights activists have campaigned against Imutran's research.
The Campaign for Responsible Transplantation, a pressure group critical of xenotransplantation, branded the move by Novartis as an attempt to duck the negative public sentiment in Europe and to take advantage of a more relaxed regulatory climate in the United States.
But Paul Herrling, head of global research at Novartis, dismisses the idea that the plan was a response to recent bad publicity. He does concede, however, that the United States already has defined regulatory criteria that would allow human trials.
Novartis will invest $30 million over three years to take a two-thirds stake in the new company, with BioTransplant owning the other third. It says all relevant Imutran operations will move to the new company.
Rights and permissions
About this article
Cite this article
Netting, J. Novartis axes UK transplant centre. Nature 407, 547 (2000). https://doi.org/10.1038/35036712
Issue Date:
DOI: https://doi.org/10.1038/35036712